Resources

Sep 22, 2020 | 17:00 - 18:00 (CET)

Topic: Making Ideas Work: Pitch Decks and Business Plans

Speaker: Prof. Sven Ripsas

-------------------------------------------------

Recommended Materials

Das Start-up-Cockpit für Unternehmensgründer: Erfolgreich von der Idee zum Proof-of-Concept by Sven Ripsas (2020)

Sven Ripsas, Professor of Entrepreneurship, founder and angel investor published very recently his book "Das Start-up-Cockpit für Unternehmensgründer: Erfolgreich von der Idee zum Proof-of-Concept". The Start-up Cockpit is designed as a control instrument for data-driven business model analysis. It helps founders to avoid wasting resources and to build a profitable company as quickly as possible. The book is currently only available in German.

Business Model Generation: A Handbook for Visionaries, Game-Changers, and Challengers by Alexander Osterwalder & Yves Pugneur (2010)

Alexander Osterwalder invented the Business Model Canvas during his doctoral dissertation. The Business Model Canvas is a framework for visualizing business models. The tool quickly spread from Europe to the US and is now applied in leading organizations and startups worldwide. The framework was explained in the bestselling management book "Business Model Generation: A Handbook for Visionaries, Game-Changers, and Challengers“, which Alexander co-authored with his former thesis supervisor Yves Pigneur.

Find out more about concept of the Business Model Canvas in this 2-minute video.

Strategyzer

Alexander Osterwalder co-founded Strategyzer (former BusinessModelDesign.com). The software company specializes in tools and content needed for business strategy and innovation. Within the Strategyzer software you can rapidly sketch business ideas, test, and share them using different visual practical tools such as the business model canvas.

The Lean Startup Movement

Eric Ries, a serial entrepreneur, co-created the lean startup movement. In the book, The Lean Startup, he presented the lean methodology that helps startups avoid failing. One of the key components of the lean methodology is the build-measure-learn feedback loop.The lean startup has been adopted by entrepreneurs worldwide.

Steve Blank, co-inventor of the lean startup movement, is considered as the father of modern entrepreneurship. The serial Sillicon Vally entrepreneur, former investor, author and now turned educator blogs at www.steveblank.com.

Video "Welcome Note and Overview of the day – Kevin Grimes, SPARK Co-Director"
Video "SPARKee Story – Prof. Craig Garner, SPARK Berlin founder"

Translation

Rescuing the Lost in Translation (2016) by Sinje Gehr and Craig C Garner
Moving medicine forward faster (2015)
Repair Reproducibility (2014)
Stanford program gives discoveries a shot at commercialization (2011)

Public-Private Relationships

Capponi L, Trinh-Shevrin C, Cronstein BN, Hochman JS. A public-private partnership: the New York University-Health and Hospitals Corporation Clinical and Translational Science Institute. Clin Transl Sci. 2012;5(3):223-5.

Luijten PR, van Dongen GA, Moonen CT, Storm G, Crommelin DJ. Public-private partnerships in translational medicine: concepts and practical examples. J Control Release. 2012;161(2):416-21.

Murphy DG, Goldman M, Loth E, Spooren W. Public-private partnership: a new engine for translational research in neurosciences. Neuron. 2014;84(3):533-6.

Peng X. University spin-offs: opportunity or challenge? Nat Mater. 2006;5(12):923-5.

Bouchie A, Allison M, Webb S, DeFrancesco L. Nature Biotechnology's academic spinouts of 2013. Nature biotechnology. 2014;32(3):229-38.

Bouchie A, DeFrancesco L. Nature Biotechnology's academic spinouts of 2014. Nature biotechnology. 2015;33(3):247-55.

Sorkness CA, Pfund C, Asquith P, Drezner MK. Research mentor training: initiatives of the University of Wisconsin Institute for Clinical and Translational Research. Clin Transl Sci. 2013;6(4):256-8.

Aguilar A, Magnien E, Thomas D. Thirty years of European biotechnology programmes: from biomolecular engineering to the bioeconomy. N Biotechnol. 2013;30(5):410-25.

Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840-2. Epub 2008/06/13.

Duda GN, Grainger DW, Frisk ML, Bruckner-Tuderman L, Carr A, Dirnagl U, Einhaupl KM, Gottschalk S, Gruskin E, Huber C, June CH, Mooney DJ, Rietschel ET, Schutte G, Seeger W, Stevens MM, Urban R, Veldman A, Wess G, Volk HD. Changing the mindset in life sciences toward translation: a consensus. Sci Transl Med. 2014;6(264):264cm12. Epub 2014/11/28.

Gehr S, Garner CC. Rescuing the Lost in Translation. Cell. 2016; 165(4): 765-770.

Germann PG, Schuhmacher A, Harrison J, Law R, Haug K, Wong G. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective. Hum Genomics. 2013;7:5.

Goldman M. The innovative medicines initiative: a European response to the innovation challenge. Clin Pharmacol Ther. 2012;91(3):418-25.

Klech H, Brooksbank C, Price S, Verpillat P, Buhler FR, Dubois D, Haider N, Johnson C, Linden HH, Payton T, Renn O, See W. European initiative towards quality standards in education and training for discovery, development and use of medicines. Eur J Pharm Sci. 2012;45(5):515-20.

Knowlton AA, Rainwater JA, Chiamvimonvat N, Bonham AC, Robbins JA, Henderson S, Meyers FJ. Training the translational research teams of the future: UC Davis-HHMI Integrating Medicine into Basic Science program. Clin Transl Sci. 2013;6(5):339-46.

Kocher R, Roberts B. The calculus of cures. The New England journal of medicine. 2014;370(16):1473-5.

Ledford H. Biotech boot camp. Nature. 2015;519(7544):402-5.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery. 2010;9(3):203-14.

Schubert C. Innovation: The big idea of technology transfer. Nature. 2012;484(7393):277-8. Epub 2012/04/17.

Sheft J. Technology transfer and idea commercialization. Nature biotechnology. 2008;26(6):711-2.

Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011;10(7):507-19.

Wright BD, Drivas K, Lei Z, Merrill SA. Technology transfer: Industry-funded academic inventions boost innovation. Nature. 2014;507(7492):297-9. Epub 2014/03/22.

Kirschenbaum SR. Patenting basic research: myths and realities. Nat Neurosci. 2002;5 Suppl:1025-7.

Lei Z, Juneja R, Wright BD. Patents versus patenting: implications of intellectual property protection for biological research. 2009:[36-40 pp.].

Murray F, Stern S. Do formal intellectual property rights hinder the free flow of scientific knowledge?: An empirical test of the anti-commons hypothesis. Journal of Economic Behavior & Organization. 2007;63(4):648-87

Reitzig M. Strategic management of intellectual property. MIT Sloan Management Review. 2004;45(3):35-40

Baell J, Walters MA. Chemistry: Chemical con artists foil drug discovery. Nature. 2014;513(7519):481-3. Epub 2014/09/26.

Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-3.

Dosa PI, Georg GI, Gurvich VJ, Hawkinson JE, Walters MA, Wong HL. From HTS to Phase I: the Institute for Therapeutics Discovery and Development at the University of Minnesota. Comb Chem High Throughput Screen. 2014;17(3):231-40.

Everitt JI. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. Toxicologic pathology. 2015;43(1):70-7.

Lombardino JG, Lowe JA, 3rd. The role of the medicinal chemist in drug discovery--then and now. Nature reviews Drug discovery. 2004;3(10):853-62.

Manns MP. [Role of academic medicine for innovations in development of drugs and biomedicine technology]. Dtsch Med Wochenschr. 2013;138(40):1993-4.

Pelkonen O, Turpeinen M, Raunio H. In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. Clinical pharmacokinetics. 2011;50(8):483-91.

Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nature reviews Drug discovery. 2011;10(9):712.

Pritchard JF, Jurima-Romet M, Reimer ML, Mortimer E, Rolfe B, Cayen MN. Making better drugs: Decision gates in non-clinical drug development. Nature reviews Drug discovery. 2003;2(7):542-53.

Prueksaritanont T, Tang C. ADME of biologics-what have we learned from small molecules? The AAPS journal. 2012;14(3):410-9.

Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011;10(7):507-19.

van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nature reviews Drug discovery. 2003;2(3):192-204.

Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical research. 2005;22(1):11-23.

Vaudano E. The innovative medicines initiative: a public private partnership model to foster drug discovery. Comput Struct Biotechnol J. 2013;6:e201303017.

Begley CG. Six red flags for suspect work. Nature. 2013;497(7450):433-4.

Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-3.

Bissell M. Reproducibility: The risks of the replication drive. Nature. 2013;503(7476):333-4.

Everitt JI. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. Toxicologic pathology. 2015;43(1):70-7.

Freedman LP, Inglese J. The increasing urgency for standards in basic biologic research. Cancer research. 2014;74(15):4024-9.

Peers IS, Ceuppens PR, Harbron C. In search of preclinical robustness. Nature reviews Drug discovery. 2012;11(10):733-4.

Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nature reviews Drug discovery. 2011;10(9):712.

Public Funding

Bundesministerium für Wirtschaft und Energie
Bundesministerium für Bildung und Forschung
Berlin Institute of Health
European Union

Public-Private Funding

High-Tech Gründerfonds